|Dr. Claudio Bordignon M.D.||Founder, Chairman, Pres and Chairman of Scientific Advisory Board||674k||N/A||N/A|
|Dr. Riccardo Palmisano||Chief Exec. Officer and Director||601k||N/A||N/A|
|Mr. Gian Paolo Rizzardi M.D.||Gen. Mang. of R&D & Operations and Director of R&D||262k||N/A||N/A|
|Ms. Marina Del Bue B.Sc., M.B.A.||Bus. Devel. & IR Director and Gen. Mang. Bus. & Admin.||30k||N/A||N/A|
|Mr. Andrea Quaglino||Chief Financial Officer and Director of Admin., Fin. & Control||N/A||N/A||N/A|
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. The companys products include Zalmoxis (TK), a cell based therapy product, which is in Phase III clinical trial in acute leukemia that is used for the treatment of hematological malignancies. Its products also comprise NGR-hTNF, a therapeutic agent for solid tumors, which is in Phase II trials in seven types of solid tumors, such as monotherapy in colorectal cancer, hepatocellular carcinoma, and mesothelioma; and in combination with standard chemotherapeutic agents in small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as in Phase III trials in mesothelioma patients. In addition, the companys preclinical development products include CAR-CD44v6, an immuno-gene therapy project for the treatment of various hematological malignancies and epithelial tumors. Further, it conducts cell and gene therapy projects in collaboration with third parties, such as the cGMP production of clinical-grade viral vectors; and manufacturing of patient-specific genetically engineered cells. The company was founded in 1996 and is headquartered in Milan, Italy.
MolMed S.p.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.